Kevin Hudson

1.5k total citations
30 papers, 1.1k citations indexed

About

Kevin Hudson is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Kevin Hudson has authored 30 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 11 papers in Oncology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Kevin Hudson's work include PI3K/AKT/mTOR signaling in cancer (5 papers), Advanced Breast Cancer Therapies (4 papers) and Ubiquitin and proteasome pathways (4 papers). Kevin Hudson is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (5 papers), Advanced Breast Cancer Therapies (4 papers) and Ubiquitin and proteasome pathways (4 papers). Kevin Hudson collaborates with scholars based in United Kingdom, France and United States. Kevin Hudson's co-authors include Dario R. Alessi, Kay S. Walker, Philip Cohen, Andrew D. Paterson, Mária Deák, Sylvie M. Guichard, Anna D. Staniszewska, Rebecca Ellston, Jason G. Kettle and Richard A. Ward and has published in prestigious journals such as Nucleic Acids Research, PLoS ONE and Cancer Research.

In The Last Decade

Kevin Hudson

29 papers receiving 1.1k citations

Peers

Countries citing papers authored by Kevin Hudson

Since Specialization

Citations

This map shows the geographic impact of Kevin Hudson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kevin Hudson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kevin Hudson more than expected).

Fields of papers citing papers by Kevin Hudson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kevin Hudson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kevin Hudson. The network helps show where Kevin Hudson may publish in the future.

Co-authorship network of co-authors of Kevin Hudson

This figure shows the co-authorship network connecting the top 25 collaborators of Kevin Hudson. A scholar is included among the top collaborators of Kevin Hudson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kevin Hudson. Kevin Hudson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	PI3Kδ Forms Distinct Multiprotein Complexes at the TCR Signalosome in Naïve and Differentiated CD4+ T Cells 2021 ·Frontiers in Immunology ·(unknown), Katarzyna Wojdyła, David Oxley, Tamara Chessa, Kevin Hudson, Phillip T. Hawkins, Len Stephens, Simon T. Barry, Klaus Okkenhaug	12
2	PI3Kα/δ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8+ T-cell activity 2018 ·Journal for ImmunoTherapy of Cancer ·Larissa S. Carnevalli, Charles Sinclair, Molly A. Taylor, Pablo Morentin Gutierrez, Sophie Langdon, Anna Coenen-Stass, Lorraine Mooney, Adina Hughes, (unknown), Anna D. Staniszewska, Claire Crafter, Ben S. Sidders, Elizabeth Hardaker, Kevin Hudson, Simon T. Barry	71
3	Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS 2017 ·Science Translational Medicine ·Sarah J. Ross, Alexey S. Revenko, Lyndsey Hanson, Rebecca Ellston, Anna D. Staniszewska, Nicky Whalley, Sanjay K. Pandey, Mitchell Revill, Claire Rooney, Linda K. Buckett, Stéphanie Klein, Kevin Hudson, Brett P. Monia, Michael Zinda, David C. Blakey, Paul D. Lyne, A. Robert MacLeod	143
4	The use of 18F-Fluoro-deoxy-glucose positron emission tomography (18F-FDG PET) as a non-invasive pharmacodynamic biomarker to determine the minimally pharmacologically active dose of AZD8835, a novel PI3Kα inhibitor 2017 ·PLoS ONE ·Juliana Maynard, (unknown), (unknown), Hervé Barjat, (unknown), Urs J. Hancox, Urszula M. Polanska, Alison Pritchard, Kevin Hudson	6
5	Discovery of a novel aminopyrazine series as selective PI3Kα inhibitors 2017 ·Bioorganic & Medicinal Chemistry Letters ·Bernard Barlaam, Sabina Cosulich, Martina Fitzek, (unknown), Stephen Green, Lyndsey Hanson, Craig S. Harris, Urs J. Hancox, Kevin Hudson, Christine Lambert‐van der Brempt, (unknown), (unknown), Gilles Ouvry, Ken Page, Linette Ruston, Lara Ward, Bénédicte Delouvrié	5
6	Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA -Dependent Breast Cancers 2016 ·Molecular Cancer Therapeutics ·Kevin Hudson, Urs J. Hancox, Cath Trigwell, Robert McEwen, Urszula M. Polanska, (unknown), Pablo Morentin Gutierrez, Alvaro Avivar‐Valderas, Oona Delpuech, Phillippa Dudley, Lyndsey Hanson, Rebecca Ellston, (unknown), Marie Cumberbatch, Sabina Cosulich, Lara Ward, Francisco Cruzalegui, Stephen Green	36
7	A Generic Platform for Cellular Screening Against Ubiquitin Ligases 2016 ·Scientific Reports ·Timurs Maculins, (unknown), Thierry Dorval, Kevin Hudson, J. Willem M. Nissink, Ronald T. Hay, (unknown)	15
8	Identification of DYRK1B as a substrate of ERK1/2 and characterisation of the kinase activity of DYRK1B mutants from cancer and metabolic syndrome 2015 ·Cellular and Molecular Life Sciences ·(unknown), Tom Dunkley, Mark Cockerill, Rachel Rowlinson, (unknown), (unknown), Kathryn Balmanno, Louise Goodwin, Richard A. Ward, Pamela A. Lochhead, Sylvie M. Guichard, Kevin Hudson, Simon J. Cook	27
9	Design of selective PI3Kα inhibitors starting from a promiscuous pan kinase scaffold 2015 ·Bioorganic & Medicinal Chemistry Letters ·Bernard Barlaam, Sabina Cosulich, Martina Fitzek, Stephen Green, Craig S. Harris, Kevin Hudson, Christine Lambert‐van der Brempt, Gilles Ouvry, Ken Page, Linette Ruston, Lara Ward, Bénédicte Delouvrié	7
10	Modeling RAS Phenotype in Colorectal Cancer Uncovers Novel Molecular Traits of RAS Dependency and Improves Prediction of Response to Targeted Agents in Patients 2013 ·Clinical Cancer Research ·Justin Guinney, Charles Ferté, Jonathan R. Dry, Robert McEwen, Gilles Manceau, (unknown), Kai‐Ming Chang, Claus Bendtsen, Kevin Hudson, Erich Huang, Brian Dougherty, Michel Ducreux, Jean‐Charles Soria, Stephen Friend, Jonathan M.J. Derry, Pierre Laurent‐Puig	30
11	Design and Synthesis of Novel Lactate Dehydrogenase A Inhibitors by Fragment-Based Lead Generation 2012 ·Journal of Medicinal Chemistry ·Richard A. Ward, C. Brassington, Alexander L. Breeze, Alessandro T. Caputo, Susan E. Critchlow, Gareth M. Davies, Louise Goodwin, (unknown), Ryan Greenwood, Geoffrey A. Holdgate, Michael Mrosek, Richard A. Norman, Stuart E. Pearson, Jonathan Tart, Julie A. Tucker, Martin Vogtherr, David Whittaker, Jonathan Wingfield, Jon Winter, Kevin Hudson	126
12	Discovery of novel imidazo[1,2-a]pyridines as inhibitors of the insulin-like growth factor-1 receptor tyrosine kinase 2011 ·Bioorganic & Medicinal Chemistry Letters ·Richard Ducray, Iain Simpson, Frédéric Jung, J. Willem M. Nissink, Peter W. Kenny, Martina Fitzek, Graeme E. Walker, Lara Ward, Kevin Hudson	44
13	Enzymatic Characterisation of USP7 Deubiquitinating activity and Inhibition 2011 ·Cell Biochemistry and Biophysics ·Jonathan D.J. Wrigley, (unknown), (unknown), (unknown), Michael A. Walters, S W Peters, Richard Mott, Thorsten Nowak, Richard A. Ward, Peter B. Simpson, Kevin Hudson	21
14	Neutral 5-substituted 4-indazolylaminoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase 2008 ·Bioorganic & Medicinal Chemistry Letters ·Bernard Barlaam, David Acton, Peter Ballard, Robert H. Bradbury, Darren A.E. Cross, Richard Ducray, (unknown), Kevin Hudson, Teresa Klinowska, (unknown), Donald Ogilvie, Annie Olivier, (unknown), (unknown), Cath Trigwell, (unknown), (unknown)	10
15	A new series of neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase 2007 ·Bioorganic & Medicinal Chemistry Letters ·Bernard Barlaam, Peter Ballard, Robert H. Bradbury, Richard Ducray, (unknown), D. Mark Hickinson, Kevin Hudson, Jason G. Kettle, Teresa Klinowska, (unknown), Donald Ogilvie, Annie Olivier, Stuart E. Pearson, James S. Scott, Abid Suleman, Cath Trigwell, (unknown), (unknown), Robin Wood	18
16	Novel 4-anilinoquinazolines with C-6 carbon-linked side chains: Synthesis and structure–activity relationship of a series of potent, orally active, EGF receptor tyrosine kinase inhibitors 2006 ·Bioorganic & Medicinal Chemistry Letters ·Laurent Hennequin, Peter Ballard, (unknown), Bénédicte Delouvrié, Rebecca Ellston, (unknown), Craig S. Harris, Kevin Hudson, Jane Kendrew, J. Elizabeth Pease, (unknown), Peter D. Smith, (unknown)	22
17	Multiple roles of the Dcdc42 GTPase during wing development in Drosophila melanogaster 2000 ·Molecular and General Genetics MGG ·Maayan Baron, Valerie B. O’Leary, D.A.P. Evans, (unknown), Kevin Hudson	15
18	The mitotic spindle and DNA damage-induced apoptosis 2000 ·Toxicology Letters ·Peter Johnson, Paula Clements, Kevin Hudson, Keith W. Caldecott	6
19	LCR/MEL: A versatile system for high-level expression of heterologous proteins in erythroid cells 1992 ·Nucleic Acids Research ·M. Needham, Clare Gooding, Kevin Hudson, Michael Antoniou, Frank Grosveld, Michael Hollis	50
20	The acid-catalysed hydrolysis and protonation behaviour of hydroxamic acids 1971 ·Journal of the Chemical Society B Physical Organic ·Alan J. Buglass, Kevin Hudson, J. G. Tillett	18

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact